In 2010, we reported improvement of liver tests under fenofibrate for 6 to 12 months in some PSC patients with an incomplete biochemical response to UDCA. Aim: To confirm the safety and efficacy of fibrates in a PSC population

with extended number of patients and duration of therapy.Methods: This retrospective single-center study included patients with PSC treated with fibrates (fenofibrate selleck inhibitor 200mg/d or bezafibrate 400 mg/d) for at least 6 months in addition to UDCA, after an incomplete biochemical response (ALP ≥ 1.5 ULN) to UDCA (15-20mg/kg/d for at least 1 year). Patients with associated liver diseases, especially auto-immune hepatitis, were not included. ANOVA and Wilcoxon tests were performed to compare serum liver biochemistries at baseline,

3, 6, 9, 12, 18, 24, 36 and 48 months. Results: Fifteen patients were included : 10 males, median age 51 years, 9 with inflammatory bowel disease, median liver stiffness = 12.7 kPa (corresponding to fibrosis ≥ F3). Median duration of treatment with fibrates was 17.5 months (6.7-60.8). Under treatment with fibrates, ALP, GGT and ALT decreased significantly (p= 0.0001, 0.02 and 0.02 respectively). Biochemical improvement occurred early and 55% patients had ALP ≤1.5 ULN at 3 months.Total bilirubin and albumin remained unchanged. Two patients with dominant biliary stenosis developed cholelithiasis. No serious adverse event related to fibrates occurred. Conclusion:This selleck compound study confirms that addition of fibrates induces a significant

biochemical improvement in PSC patients with incomplete response to UDCA. Further studies are warranted to investigate the potential clinical benefit of fibrates in this context. Course of liver tests during treatment with fibrates Disclosures: Olivier Chazouillères – Consulting: APTALIS, MAYOLY-SPINDLER The following people have nothing to disclose: Sara Lemoinne, Christophe Corpechot, Astrid Donald D. Kemgang Fankem, Farid Elongation factor 2 kinase Gaouar, Raoul Poupon More than 80% of patients with autoimmune hepatitis are good responders to conventional treatment with azathioprine and prednisone. A small proportion of patients flares during prednisone tapering (treatment-dependent patients) according to AASLD guideline. We aimed to define response-related parameters in patients with autoimmune hepatitis (AH). Methods: The patients with AH who were followed up for at least 6 months were included into the study. Treatment-dependency was defined as ALT elevation during prednisolon tapering. Those remained in remission with maintenance dose of prednisolon and/or azathioprine were defined as good responder(GR).